" class="no-js "lang="en-US"> NeuroSense Therapeutics - Medtech Alert
Sunday, August 03, 2025
NeuroSense Therapeutics | Pharmtech Focus

NeuroSense Therapeutics

About NeuroSense Therapeutics

NeuroSense Therapeutics

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

Related Story

NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial

May 16 2023

NeuroSense Therapeutics, a company developing treatments for severe neurodegenerative diseases, today announced the completion of […]

NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS

March 27 2023

NeuroSense Therapeutics, a company developing treatments for severe neurodegenerative diseases, today announced it has signed […]